Oncology News | pharmaphorum

News

"Significant shift" as NICE widens prostate cancer drug use

NICE has changed unpopular guidance on abiraterone for hormone-sensitive prostate cancer after the entry of generics into the UK market.

News

Blue ribbon for prostate cancer awareness

As UK mulls prostate cancer screening, study shows benefit

New data have shown that the balance between the benefits and harms of prostate cancer screening has improved with longer follow-up.

News

MSD, Eisai abandon combination trial in liver cancer

MSD and Eisai's oncology partnership has had mixed fortunes this week, with a disappointment in liver cancer and encouraging data in kidney cancer.

News

As Blenrep returns, GSK adds another ADC to cancer pipeline

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia.

News

A male HCP discusses treatment with an older male patient

Bayer's prostate cancer drug Nubeqa cleared for NHS use

Thousands of men living with incurable prostate cancer will be able to access an easier-to-tolerate treatment from Bayer, thanks to new NICE guidance.

News

GSK's Blenrep's back in US, but with a narrower label

Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed from sale.

"Significant shift" as NICE widens prostate cancer drug use

As UK mulls prostate cancer screening, study shows benefit

MSD, Eisai abandon combination trial in liver cancer

As Blenrep returns, GSK adds another ADC to cancer pipeline

Bayer's prostate cancer drug Nubeqa cleared for NHS use

GSK's Blenrep's back in US, but with a narrower label

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks